Analyst Expectations for Pacific Biosciences's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Pacific Biosciences (NASDAQ:PACB) within the last quarter, with 2 bullish and 3 indifferent. The company has an average 12-month price target of $14.8, which has increased by 13.85% over the past month.
August 22, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pacific Biosciences has received mixed ratings from analysts, with a 12-month price target of $14.8.
The mixed ratings from analysts indicate uncertainty about the company's future performance. However, the increase in the 12-month price target suggests a positive outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100